QuidelOrtho (QDEL)
(Real Time Quote from BATS)
$43.43 USD
-1.96 (-4.32%)
Updated Sep 25, 2024 03:24 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
QDEL 43.43 -1.96(-4.32%)
Will QDEL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QDEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QDEL
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
QDEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates
Other News for QDEL
QuidelOrtho Corp (QDEL) Stock Price Down 4.21% on Sep 25
Cracking The Code: Understanding Analyst Reviews For QuidelOrtho
Five Below downgraded, DoorDash upgraded: Wall Street's top analyst calls
QuidelOrtho assumed with Neutral from Sell at UBS
Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.